NLRP3 and tuberculosis: While ouabain monotherapy significantly reduced inflammation, the incomplete normalization of NLRP3/IL-1β levels suggests two complementary strategies: Low-dose corticosteroids could augment ouabain’s immunomodulation while minimizing toxicity, as shown in tuberculosis models.